Underserved spine Target opportunities in facetogenic and sacroiliac joint pain, where surgical options are limited and patients rely on repeated palliative treatments. Position Zyga's SImmetry and Glyder devices as transformative solutions that reduce dependency on injections and streamline care pathways.

Clinical momentum Leverage historical milestones and ongoing trials such as EVSI and 24‑month CT fusion data to engage prospective customers with proven clinical results, accelerating adoption conversations and payer justification for minimally invasive spine solutions.

Strategic partnerships Highlight Zyga's acquisition history and backing by larger entities, signaling stability and growth potential. Use this to open dialogues with large hospital systems and distributors seeking innovative spine technologies with a credible track record.

Funding and scale With substantial funding history ($82M) and a lean employee base, position Zyga as a nimble innovator capable of rapid market entry and support scale. Propose pilot programs and flexible commercialization plans to healthcare networks.

Market leadership Capitalize on the sizable TAM of low back pain due to facetogenic and SI joint issues by aligning with institutions focused on value-based care. Use evidence of unmet need and positive clinical outcomes to differentiate Zyga from competitors and drive targeted outreach to spine centers and orthopedics.